<?xml version='1.0' encoding='utf-8'?>
<document id="26831715"><sentence text="Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors."><entity charOffset="33-43" id="DDI-PubMed.26831715.s1.e0" text="Linsitinib" /><entity charOffset="58-67" id="DDI-PubMed.26831715.s1.e1" text="Erlotinib" /><pair ddi="false" e1="DDI-PubMed.26831715.s1.e0" e2="DDI-PubMed.26831715.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26831715.s1.e0" e2="DDI-PubMed.26831715.s1.e1" /></sentence><sentence text="Cross-talk between type I IGF receptor (IGF1R), insulin receptor (INSR), and epidermal growth factor receptor (EGFR) mediates resistance to individual receptor blockade" /><sentence text=" This study aimed to determine the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of linsitinib, a potent oral IGF1R/INSR inhibitor, with EGFR inhibitor erlotinib"><entity charOffset="122-132" id="DDI-PubMed.26831715.s3.e0" text="linsitinib" /><entity charOffset="190-199" id="DDI-PubMed.26831715.s3.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.26831715.s3.e0" e2="DDI-PubMed.26831715.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26831715.s3.e0" e2="DDI-PubMed.26831715.s3.e1" /></sentence><sentence text="" /><sentence text="This open-label, dose-escalation study investigated linsitinib schedules S1: once daily intermittent (days 1-3 weekly); S2, once daily continuous; S3, twice-daily continuous; each with erlotinib 100-150 mg once daily; and a non-small cell lung cancer (NSCLC) expansion cohort"><entity charOffset="185-194" id="DDI-PubMed.26831715.s5.e0" text="erlotinib" /></sentence><sentence text="" /><sentence text="Ninety-five patients were enrolled (S1, 44; S2, 24; S3, 12; expansion cohort, 15) and 91 treated" /><sentence text=" Seven experienced dose-limiting toxicities: QTc prolongation (3), abnormal liver function (2), hyperglycemia (1), and anorexia (1)" /><sentence text=" Common adverse events included drug eruption (84%), diarrhea (73%), fatigue (68%), nausea (58%), vomiting (40%)" /><sentence text=" MTDs for linsitinib/erlotinib were 450/150 mg (S1), 400/100 mg (S2)"><entity charOffset="10-20" id="DDI-PubMed.26831715.s10.e0" text="linsitinib" /><entity charOffset="21-30" id="DDI-PubMed.26831715.s10.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.26831715.s10.e0" e2="DDI-PubMed.26831715.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26831715.s10.e0" e2="DDI-PubMed.26831715.s10.e1" /></sentence><sentence text=" On the basis of prior monotherapy data, S3 dosing at 150 mg twice daily/150 mg once daily was the recommended phase II dose for the expansion cohort" /><sentence text=" There was no evidence of drug-drug interaction" /><sentence text=" Pharmacodynamic data showed IGF-1 elevation and reduced IGF1R/INSR phosphorylation, suggesting pathway inhibition" /><sentence text=" Across schedules, 5/75 (7%) evaluable patients experienced partial responses: spinal chordoma (268+ weeks), rectal cancer (36 weeks), three NSCLCs including 2 adenocarcinomas (16, 72 weeks), 1 squamous wild-type EGFR NSCLC (36 weeks)" /><sentence text=" Disease control (CR+PR+SD) occurred in 38 of 75 (51%), and 28 of 91 (31%) patients were on study &gt;12 weeks" /><sentence text="" /><sentence text="The linsitinib/erlotinib combination was tolerable with preliminary evidence of activity, including durable responses in cases unlikely to respond to erlotinib monotherapy"><entity charOffset="4-14" id="DDI-PubMed.26831715.s17.e0" text="linsitinib" /><entity charOffset="15-24" id="DDI-PubMed.26831715.s17.e1" text="erlotinib" /><entity charOffset="150-159" id="DDI-PubMed.26831715.s17.e2" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.26831715.s17.e0" e2="DDI-PubMed.26831715.s17.e0" /><pair ddi="false" e1="DDI-PubMed.26831715.s17.e0" e2="DDI-PubMed.26831715.s17.e1" /><pair ddi="false" e1="DDI-PubMed.26831715.s17.e0" e2="DDI-PubMed.26831715.s17.e2" /><pair ddi="false" e1="DDI-PubMed.26831715.s17.e1" e2="DDI-PubMed.26831715.s17.e1" /><pair ddi="false" e1="DDI-PubMed.26831715.s17.e1" e2="DDI-PubMed.26831715.s17.e2" /></sentence><sentence text=" Clin Cancer Res; 22(12); 2897-907" /><sentence text=" Â©2016 AACR" /><sentence text="" /></document>